These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 22122202)

  • 21. Long-term safety and efficacy of indacaterol, a long-acting β₂-agonist, in subjects with COPD: a randomized, placebo-controlled study.
    Chapman KR; Rennard SI; Dogra A; Owen R; Lassen C; Kramer B;
    Chest; 2011 Jul; 140(1):68-75. PubMed ID: 21349928
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD.
    Beeh KM; Wagner F; Khindri S; Drollmann AF
    COPD; 2011 Oct; 8(5):340-5. PubMed ID: 21793716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison.
    Rennard S; Bantje T; Centanni S; Chanez P; Chuchalin A; D'Urzo A; Kornmann O; Perry S; Jack D; Owen R; Higgins M
    Respir Med; 2008 Jul; 102(7):1033-44. PubMed ID: 18479895
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma.
    Beeh KM; Derom E; Kanniess F; Cameron R; Higgins M; van As A
    Eur Respir J; 2007 May; 29(5):871-8. PubMed ID: 17251236
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients.
    Van de Maele B; Fabbri LM; Martin C; Horton R; Dolker M; Overend T
    COPD; 2010 Dec; 7(6):418-27. PubMed ID: 21166630
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of once-daily indacaterol relative to alternative bronchodilators in COPD: a patient-level mixed treatment comparison.
    Cope S; Capkun-Niggli G; Gale R; Lassen C; Owen R; Ouwens MJ; Bergman G; Jansen JP
    Value Health; 2012 May; 15(3):524-33. PubMed ID: 22583463
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design.
    Barnes PJ; Pocock SJ; Magnussen H; Iqbal A; Kramer B; Higgins M; Lawrence D
    Pulm Pharmacol Ther; 2010 Jun; 23(3):165-71. PubMed ID: 20080201
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of indacaterol and tiotropium in COPD patients according to dyspnoea severity.
    Mahler DA; Buhl R; Lawrence D; McBryan D
    Pulm Pharmacol Ther; 2013 Jun; 26(3):348-55. PubMed ID: 23434446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study.
    Decramer ML; Chapman KR; Dahl R; Frith P; Devouassoux G; Fritscher C; Cameron R; Shoaib M; Lawrence D; Young D; McBryan D;
    Lancet Respir Med; 2013 Sep; 1(7):524-33. PubMed ID: 24461613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monotherapy with indacaterol once daily reduces the rate of exacerbations in patients with moderate-to-severe COPD: Post-hoc pooled analysis of 6 months data from three large phase III trials.
    Wedzicha JA; Buhl R; Lawrence D; Young D
    Respir Med; 2015 Jan; 109(1):105-11. PubMed ID: 25433954
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison.
    Mahler DA; D'Urzo A; Bateman ED; Ozkan SA; White T; Peckitt C; Lassen C; Kramer B;
    Thorax; 2012 Sep; 67(9):781-8. PubMed ID: 22544891
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol.
    Cazzola M; Segreti A; Stirpe E; Puxeddu E; Ora J; Rogliani P; Matera MG
    Respir Med; 2013 Jan; 107(1):107-11. PubMed ID: 23083839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease.
    van Noord JA; Buhl R; Laforce C; Martin C; Jones F; Dolker M; Overend T
    Thorax; 2010 Dec; 65(12):1086-91. PubMed ID: 20978028
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium.
    Rossi A; Centanni S; Cerveri I; Gulotta C; Foresi A; Cazzola M; Brusasco V
    Respir Med; 2012 Jan; 106(1):84-90. PubMed ID: 22035851
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease.
    Mahler DA; Kerwin E; Ayers T; FowlerTaylor A; Maitra S; Thach C; Lloyd M; Patalano F; Banerji D
    Am J Respir Crit Care Med; 2015 Nov; 192(9):1068-79. PubMed ID: 26177074
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Indacaterol once-daily is equally effective dosed in the evening or morning in COPD.
    Magnussen H; Verkindre C; Jack D; Jadayel D; Henley M; Woessner R; Higgins M; Kramer B;
    Respir Med; 2010 Dec; 104(12):1869-76. PubMed ID: 20850959
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of treatment with indacaterol in patients with COPD: A post-hoc analysis according to GOLD 2011 categories A to D.
    Kerstjens HA; Deslée G; Dahl R; Donohue JF; Young D; Lawrence D; Kornmann O
    Pulm Pharmacol Ther; 2015 Jun; 32():101-8. PubMed ID: 25743376
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study.
    Dahl R; Chapman KR; Rudolf M; Mehta R; Kho P; Alagappan VK; Chen H; Banerji D
    Respir Med; 2013 Oct; 107(10):1558-67. PubMed ID: 23867808
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of single therapeutic and supratherapeutic doses of indacaterol versus salmeterol and salbutamol in patients with asthma.
    Brookman LJ; Knowles LJ; Barbier M; Elharrar B; Fuhr R; Pascoe S
    Curr Med Res Opin; 2007 Dec; 23(12):3113-22. PubMed ID: 17999782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.